IL-18 may therefore be a promising factor that will contribute to novel treatment options for NAFLD or NASH mainly through correction of energy unbalances by lipids or glucose in the liver [3]. The gene discussed is IL18; the disease is metabolic dysfunction-associated steatotic liver disease.